

Annual Scientific Research Meeting

Thursday 9th October 2014 from 12:00pm to 5:00pm

Harry Perkins Institute of Medical Research, Perth, Western Australia

Agenda		
	Speaker	Time
<i>All full and associate ANZMTG members are warmly invited to attend. Refreshments will be served from 11:30am</i>		
1. Introduction and Welcome; presented by Dr Mark Shackleton		12pm-12:10pm
2. Review and discussion of ANZMTG's New Research Proposals; Session Chair: Dr Mark Shackleton		12:10pm-3:30pm
i. NRP 01.14 / ANZMTG 02.14 An open label, single arm, phase I/II multicentre study to evaluate the safety and efficacy of the combination of Dabrafenib, Trametinib and palliative radiotherapy in patients with unresectable Stage IIIc and Stage IV BRAF V600E/K mutation-positive cutaneous melanoma (CombiRT)	<i>Tim Wang</i>	20 minutes presentation & 10 minutes discussion per protocol
ii. NRP 02.14 Does knowledge of personal genetic risk of melanoma motivate behaviour change? A randomised controlled trial.	<i>Anne Cust</i>	
iii. NRP 03.14 PET and Role of Imaging / Sentinel LN biopsy in Merkel Cell Carcinoma (PRISM) – A Prospective multisite evaluation of the roles of 18F-FDG PET and SLN mapping ± biopsy in the diagnostic work-up of MCC.	<i>Louise Emmett</i>	
iv. NRP 05.14 A randomized controlled trial in T1N0 Merkel Cell Carcinoma of either radiotherapy to the primary site or wide local excision following diagnostic biopsy.	<i>Gerald Fogarty</i>	
<i>Short Break</i>		2:30pm
v. NRP 06.14 Predictive significance of circulating tumour cells (CTCs) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with immunotherapy (Ipilimumab/anti-PD1/PDL1)	<i>Adnan Khattak</i>	
vi. NRP 07.14 Stereotactic Radiosurgery versus Observation for patients with Melanoma brain metastases being started on a BRAF Inhibitor (ROMA study)	<i>Gerald Fogarty</i>	
During the discussion of each New Research Proposal feedback from consumers will be provided by Paul White		
<i>Afternoon Tea will be served - The ANZMTG Annual General Meeting will be held during this break; all full ANZMTG members are welcome.</i>		3:30pm-3:45pm
3. ANZMTG Approved Trials In Development Update; Session Chair: Dr Donna Milne		3:45pm-4:30pm
vii. ANZMTG 01.12 Inguinal or Ilio-inguinal Lymph Node Dissection for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET / CT Scan–A randomised phase III trial (EAGLE FM)	<i>Chris Allan</i>	10 minutes presentation & maximum of 5 minutes discussion per protocol
viii. ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL)	<i>Gerald Fogarty</i>	
ix. ANZMTG 03.12 Melanoma Excision Margins Trial - A phase III, multi-centre, multi-national randomised control trial investigating 1cm vs 2cm wide excision margins for primary cutaneous melanoma (MelMarT)	<i>Michael Henderson</i>	
4. Closed and Current ANZMTG Clinical Trials Update; Session Chair: Prof Bryan Burmeister		4:30pm-5pm
x. ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial (WBRTMel)	<i>Gerald Fogarty</i>	5 minutes presentation & a maximum of 5 minutes discussion per protocol
xi. ANZMTG 01.09 A randomised trial of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck (RTN2)	<i>Bryan Burmeister</i>	
xii. ANZMTG 02.09 Vitamin D Following Primary Treatment of Melanoma at High Risk of Recurrence (Mel-D)	<i>John Thompson</i>	
xiii. ANZMTG 01.13 A randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease.	<i>Anne Cust</i>	
xiv. ANZMTG and Consumers Working Together for Improved Awareness, Research and Funding into Melanoma	<i>Paul White</i>	10 minutes
5. Concluding Remarks led by Prof Bryan Burmeister		5:00pm
<i>The SKMRC Welcome Function held at the same venue (from 5:30pm to 7:30pm) – all ANZMTG members are invited to</i>		